Press calls for tough new commissioner at the US FDA
This article was originally published in Clinica
Executive Summary
Editorial commentators in the US press are calling for President Clinton to name an equally tough and aggressive person to replace David Kessler, who resigned last month as commissioner of the FDA. A paean of praise to Dr Kessler for setting a high regulatory standard has echoed round most major newspapers.
You may also be interested in...
A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Go-Ahead For Appointment Of European Union Reference Labs For IVDs
EURLs have been a critical missing element of the IVDR for assessing the higher-risk class D IVDs. Two new implementing regulations, on fees and tasks, bring them closer to designation.
Stock Watch: Protocol Changes Preface Poor Trial Outcomes
It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?